

EXPORT LICENSE

NRC FORM 250



United States of America
Nuclear Regulatory Commission
Washington, D.C. 20555

NRC LICENSE NO.: XMAT422/03

Page 1 of 7

NRC DOCKET NO.: 11005997

LICENSE EXPIRES: May 31, 2024

Pursuant to the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974 and the regulations of the Nuclear Regulatory Commission (NRC) issued pursuant thereto, and in reliance on the statements and representations herefore made by the licensee, a license is hereby issued to the licensee authorizing the export of the materials and/or production or utilization facilities listed below, subject to the terms and conditions herein.

LICENSEE Cambridge Isotope Laboratories Inc. 50 Frontage Road Andover, MA 01810 Attn: Gary Ionta		ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES) See following page(s)	
INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES) See following page(s)		OTHER U.S. PARTY(IES) TO EXPORT None	
APPLICANT'S REFERENCE: Appl dated 02/02/2018		ULTIMATE DESTINATION: China	
QUANTITY(IES) 10,000 kilograms	DESCRIPTION OF MATERIAL(S) OR FACILITY(IES) This license is amended to include six additional ultimate consignees and extend the date of expiration from January 1, 2022 to May 31, 2024. The licensee is authorized to export a cumulative total of 10,000 kilograms of deuterium, in the form of deuterium oxide, deuterium gas, and other compounds. The cumulative total starts from the issuance of original export license XMAT422. CONDITION: A license amendment request is required for the addition of intermediate consignees not listed on this export license.		
Neither this license nor any right under this license shall be assigned or otherwise transferred in violation of the provisions of the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974. This license is subject to the right of recapture or control by Section 108 of the Atomic Energy Act of 1954, as amended, and to all the other provisions of said Acts, now or hereafter in effect and to all valid rules and regulations of the NRC.		THIS LICENSE IS INVALID UNLESS SIGNED BELOW BY AUTHORIZED NRC REPRESENTATIVE SIGNATURE: <u>Mohamed K. Shams</u> <small>Digitally signed by Mohamed K. Shams Date: 2019.11.22 11:35:09 -05'00'</small> NAME AND TITLE: <u>Mohamed K. Shams, Acting Deputy Director Office of International Programs</u> DATE OF ISSUANCE: <u>November 22, 2019</u>	

EXPORT LICENSE

ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

1. [REDACTED]

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

2. [REDACTED]

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

3. [REDACTED]

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

4. [REDACTED]

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

5. [REDACTED]

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

6. [REDACTED]

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

7. [REDACTED]

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

8. [REDACTED]

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

9. [REDACTED]

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

10. [REDACTED]

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

11. [REDACTED]

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

12. [REDACTED]

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

13. [REDACTED]

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

14. [REDACTED]

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

15. [REDACTED]

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

16. [REDACTED]

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

17. [REDACTED]

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

18. [REDACTED]

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

19. [REDACTED]

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

20. [REDACTED]

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

1. [REDACTED]

(for distribution to ultimate consignees)

2. [REDACTED]

(for distribution to ultimate consignees)

3. [REDACTED]

(for distribution to ultimate consignees)

INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

4. [REDACTED]

(for distribution to ultimate consignees)

5. [REDACTED]

(for distribution to ultimate consignees)

6. [REDACTED]

(for distribution to ultimate consignees)

7. [REDACTED]

(for distribution to ultimate consignees)

8. [REDACTED]

(for distribution to ultimate consignees)

9. [REDACTED]

(for distribution to ultimate consignees)

10. [REDACTED]

(for distribution to ultimate consignees)

INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

11. [REDACTED]

(for distribution to ultimate consignees)

12. [REDACTED]

(for distribution to ultimate consignees)

13. [REDACTED]

(for distribution to ultimate consignees)

14. [REDACTED]

(for distribution to ultimate consignees)

15. [REDACTED]

(for distribution to ultimate consignees)

16. [REDACTED]

(for distribution to ultimate consignees)

17. [REDACTED]

(for distribution to ultimate consignees)

INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

18. [REDACTED]

(for distribution to ultimate consignees)

19. [REDACTED]

(for distribution to ultimate consignees)

20. [REDACTED]

(for distribution to ultimate consignees)

21. [REDACTED]

(for distribution to ultimate consignees)

22. [REDACTED]

(for distribution to ultimate consignees)